CIBMTR Chronic GVHD Risk Score Predicts Mortality in an Independent Validation Cohort. Biol Blood Marrow Transplant. 2014.
Comparative analysis of calcineurin-inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of Graft-versus-Host Disease after reduced intensity conditioning allogeneic transplantation. Biol Blood Marrow Transplant. 2018.
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol. 2020:JCO1900396.
DONOR HLA-E STATUS ASSOCIATES WITH DISEASE FREE SURVIVAL AND TRANSPLANT RELATED MORTALITY AFTER NON IN VIVO T-CELL DEPLETED HSCT FOR ACUTE LEUKEMIA. Biol Blood Marrow Transplant. 2019.
Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation. Blood. 2014.
Inferior Outcomes with Cyclosporine and Mycophenolate mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019.
Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia. Blood Adv. 2020;4(7):1350-1356..
Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow allografts have improved Long-term Overall and Graft-versus-Host Disease, Relapse-Free Survival. Biol Blood Marrow Transplant. 2018.
Pre-sensitization to HY-antigens in female donors prior to transplant is not associated with male recipient post-transplant HY-antibody development nor clinical outcomes. Haematologica. 2015.